Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Expression Analysis Expands Services

October 13, 2010 8:26 am | News | Comments

Expression Analysis, a leading provider of genomic services for clinical trials and research, announced that it has expanded its sequencing services to include single-lane sequencing with guaranteed turn-around-times and, firm fixed pricing.


Merck Presents Positive Erbitux Data

October 13, 2010 8:20 am | News | Comments

Merck KGaA announced data presented that showed that patients with KRAS wild-type metastatic colorectal cancer who experienced early tumor shrinkage during first-line Erbitux-based treatment lived a median of 28.3 months.


Prosensa Gets Milestone Payment from GSK

October 13, 2010 8:09 am | News | Comments

Prosensa received a £7.5m milestone payment from GlaxoSmithKline as a result of achieving a data milestone in its Phase 2a open label extension trial of GSK2402968 (PRO051), being developed to treat Duchenne Muscular Dystrophy.


FDA Approves Vivitrol for Drug Addiction

October 13, 2010 8:06 am | News | Comments

Drugmaker Alkermes Inc. said it has received U.S. approval to market its addiction medication for use in patients addicted to narcotics like heroin and morphine.


HIV Patients To Be Screened for TB

October 13, 2010 8:04 am | by Jenny Gross | News | Comments

Health officials in South Africa said they recommend screening all HIV patients for tuberculosis and want automatic TB tests for HIV patients to become normal procedure within five years.


Treating Relapsing-Remitting Multiple Sclerosis

October 13, 2010 7:43 am | by Kate Dawson, MD, Senior Director, Medical Research, Biogen Idec, Cambridge, Mass. | Articles | Comments

Biogen Idec’s BG-12 is an oral formulation of dimethyl fumarate. This is the first compound in clinical trials to activate the Nrf2 transcriptional pathway, a central mechanism of cellular defense against oxidative and metabolic stress.


Therapeutic Promise of Human Neural Stem Cells

October 13, 2010 7:39 am | by Stephen Huhn, MD, FACS, FAAP, Vice President, Head of the CNS Program, StemCells, Inc., Palo Alto, Calif. | Articles | Comments

Stem cells have the potential to treat a broad range of human disorders. While approaches based on embryonic stem cells and induced pluripotent stem cells have attracted the most media attention, they are complicated by specific challenges.


Unlocking the Therapeutic Potential of the NMDA Receptor

October 13, 2010 7:36 am | by Joseph R. Moskal, PhD, President and CSO; J. David Leander, PhD, Chief Scientific Advisor; and Ronald M. Burch, MD, PhD, CMO, Naurex, Inc., Evanston, Ill. | Articles | Comments

The glutamate receptor subtype known as N-methyl-D-aspartic acid (NMDA) plays a central role in modulating aspects of brain activity. Naurex is developing a pipeline that modulates the NMDA receptor (NMDAR) at the glycine site.


Glutamate Modulation as Parkinson’s Therapy

October 13, 2010 7:28 am | by Chris Maggos, Investor Relations & Communication, Addex Pharmaceuticals, Geneva, Switzerland | Articles | Comments

Glutamate is a critical neurotransmitter that is involved in a multitude of biological functions and disease processes. Despite its rich therapeutic potential, the glutamatergic system has historically been a challenge for drug discoverers.


HuCAL Antibody Combats Alzheimer’s Disease

October 13, 2010 7:22 am | by Marlies Sproll, PhD, CSO MorphoSys AG Planegg, Germany | Articles | Comments

A major challenge for Alzheimer’s disease drug candidates, particularly for therapeutic antibodies, is the blood-brain barrier. Once considered impermeable for large molecules, recent evidence has shown that they are in fact able to pass through.


Insulin Resistance Linked to Stroke

October 12, 2010 7:27 am | News | Comments

Insulin resistance, a condition in which insulin produced by the body becomes less effective in reducing blood glucose levels, appears to be associated with an increased risk of stroke in individuals without diabetes.


New Drugs for AMD Just As Safe As Older Treatments

October 12, 2010 7:11 am | News | Comments

Newer treatments for age-related macular degeneration do not appear to be associated with an increased risk of cardiovascular complications or death when compared with existing therapies.


Briakinumab Effective at Clearing Plaques

October 12, 2010 6:54 am | News | Comments

A greater percentage of moderate to severe chronic plaque psoriasis patients treated with briakinumab, Abbott's investigational IL-12/23 inhibitor, achieved 75% or better skin clearance rates than those treated with etanercept, methotrexate, or placebo.


Merck Appealing EMA Ruling

October 12, 2010 6:34 am | News | Comments

Merck KGaA has notified the European Medicines Agency of its intention to request a re-examination of the opinion issued by the Committee for Medicinal Products for Human Use regarding Cladribine Tablets for relapsing-remitting multiple sclerosis.


Court Won't Stop Hormone Replacement Lawsuits

October 12, 2010 6:18 am | News | Comments

The Supreme Court won't reconsider a decision to reinstate more than 100 lawsuits filed by women who claimed that hormone replacement therapy caused breast cancer.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.